Immunotherapy has revolutionized most cancers remedy by mobilizing the immune system to assault tumor cells. Main advances, equivalent to immune checkpoint inhibitors (notably towards the PD-1 protein), have produced spectacular outcomes towards sure sorts of most cancers, together with melanoma and kidney most cancers.
These therapies “take the brakes off” the immune system, rising its means to detect and destroy most cancers cells. Nevertheless, regardless of their effectiveness, these therapies don’t work for all sufferers or all sorts of most cancers. This realization has prompted researchers world wide to seek for new therapeutic targets.
Now comes work carried out within the laboratory of Université de Montréal medical professor Dr. André Veillette, director of the molecular oncology analysis unit of the Montreal Scientific Analysis Institute (IRCM), in collaboration with scientists from a number of nations, marks a breakthrough within the struggle towards treatment-refractory cancers.
Led by Jiaxin Li, a doctoral scholar in Veillette’s lab, the researchers have found a brand new molecule of curiosity referred to as CD200R1. The discovering is detailed in a research printed within the journal Nature Communications.
CD200R1 is a protein current on the floor of sure immune cells referred to as macrophages, which play a key function in detecting and destroying irregular cells. The brand new analysis exhibits that blocking CD200R1 with particular antibodies prompts macrophages, serving to to get rid of blood cancers equivalent to leukemia and lymphoma in preclinical mouse fashions.
These outcomes pave the best way for a brand new therapeutic strategy for cancers which might be proof against present therapies, the scientists imagine. The following step for Veillette and his staff is to develop collaborations geared toward proving that this technique also can work in people, which may rework remedy choices for a lot of sufferers.
Extra data:
Jiaxin Li et al, CD200R1-CD200 checkpoint inhibits phagocytosis in a different way from SIRPα-CD47 to suppress tumor development, Nature Communications (2025). DOI: 10.1038/s41467-025-60456-3
Quotation:
Blocking CD200R1 protein presents new technique for treatment-resistant blood cancers (2025, June 13)
retrieved 13 June 2025
from https://medicalxpress.com/information/2025-06-blocking-cd200r1-protein-strategy-treatment.html
This doc is topic to copyright. Other than any truthful dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for data functions solely.
